View Daily Data Tracking History
View Bill Text
View Statement of Purpose / Fiscal Impact
H0409........................................................by MR. SPEAKER
Requested by: Board of Pharmacy
CONTROLLED SUBSTANCES - Amends existing law to add the drug carisoprodol to
schedule IV controlled substances.
01/17 House intro - 1st rdg - to printing
Rpt prt - to Health/Wel
H0409|||| LEGISLATURE OF THE STATE OF IDAHO |||| Fifty-fifth Legislature Second Regular Session - 2000IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. 409 BY MR. SPEAKER Requested by: Board of Pharmacy 1 AN ACT 2 RELATING TO CONTROLLED SUBSTANCES; AMENDING SECTION 37-2711, IDAHO CODE, TO 3 ADD THE DRUG CARISOPRODOL TO SCHEDULE IV CONTROLLED SUBSTANCES; AND PRO- 4 VIDING AN EFFECTIVE DATE. 5 Be It Enacted by the Legislature of the State of Idaho: 6 SECTION 1. That Section 37-2711, Idaho Code, be, and the same is hereby 7 amended to read as follows: 8 37-2711. SCHEDULE IV. (a) Schedule IV shall consist of the drugs and 9 other substances, by whatever official name, common or usual name, chemical 10 name, or brand name designated, listed in this section. 11 (b) Narcotic drugs. Unless specifically excepted or unless listed in 12 another schedule, any material, compound, mixture, or preparation containing 13 any of the following narcotic drugs, or their salts calculated as the free 14 anhydrous base or alkaloid, in limited quantities as set forth below: 15 (1) No more than 1 milligram of difenoxin and not less than 25 micrograms 16 of atropine sulfate per dosage unit; 17 (2) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 18 2-diphenyl-3-methyl-2-propionoxybutane). 19 (c) Depressants. Unless specifically excepted or unless listed in another 20 schedule, any material, compound, mixture, or preparation which contains any 21 quantity of the following substances, including its salts, isomers, and salts 22 of isomers whenever the existence of such salts, isomers, and salts of isomers 23 is possible within the specific chemical designation: 24 (1) Alprazolam; 25 (2) Barbital; 26 (3) Bromazepam; 27 (4) Camazepam; 28 (5) Chloral betaine; 29 (6) Chloral hydrate; 30 (7) Chlordiazepoxide; 31 (8) Clobazam; 32 (9) Clonazepam; 33 (10) Clorazepate; 34 (11) Clotiazepam; 35 (12) Cloxazolam; 36 (13) Delorazepam; 37 (14) Diazepam; 38 (15) Estazolam; 39 (16) Ethchlorvynol; 40 (17) Ethinamate; 41 (18) Ethyl loflazepate; 42 (19) Fludiazepam; 43 (20) Flurazepam; 2 1 (21) Halazepam; 2 (22) Haloxazolam; 3 (23) Ketazolam; 4 (24) Loprazolam; 5 (25) Lorazepam; 6 (26) Lormetazepam; 7 (27) Mebutamate; 8 (28) Medazepam; 9 (29) Meprobamate; 10 (30) Methohexital; 11 (31) Methylphenobarbital (mephobarbital); 12 (32) Midazolam; 13 (33) Nimetazepam; 14 (34) Nitrazepam; 15 (35) Nordiazepam; 16 (36) Oxazepam; 17 (37) Oxazolam; 18 (38) Paraldehyde; 19 (39) Petrichloral; 20 (40) Phenobarbital; 21 (41) Pinazepam; 22 (42) Prazepam; 23 (43) Temazepam; 24 (44) Tetrazepam; 25 (45) Triazolam; 26 (46) Quazepam; 27 (47) Zolpidem. 28 (d) Fenfluramine - Any material, compound, mixture, or preparation which 29 contains any quantity of the following substances, including its salts, 30 isomers (whether optical, position, or geometric), and salts of such isomers, 31 whenever the existence of such salts, isomers, and salts of isomers is possi- 32 ble: 33 (1) Fenfluramine. 34 (e) Stimulants. Unless specifically excepted or unless listed in another 35 schedule, any material, compound, mixture, or preparation which contains any 36 quantity of the following substances having a stimulant effect on the central 37 nervous system, including its salts, isomers (whether optical, position, or 38 geometric), and salts of such isomers whenever the existence of such salts, 39 isomers, and salts of isomers is possible within the specific chemical desig- 40 nation: 41 (1) Cathine ((+)-norpseudoephedrine); 42 (2) Diethylpropion; 43 (3) Fencamfamin; 44 (4) Fenproporex; 45 (5) Mazindol; 46 (6) Mefenorex; 47 (7) Pemoline (including organometallic complexes and chelates thereof); 48 (8) Phentermine; 49 (9) Pipradrol; 50 (10) Sibutramine; 51 (11) SPA ((-)-1-dimethylamino-1,2-diphenylethane). 52 (f) Other substances. Unless specifically excepted, or unless listed in 53 another schedule, any material, compound, mixture or preparation which con- 54 tains any quantity of the following substance, including its salts: 55 (1) Pentazocine; 3 1 (2) Carisoprodol. 2 (g) The board may except by rule any compound, mixture, or preparation 3 containing any depressant substance listed in subsection (c) of this section 4 from the application of all or any part of this act if the compound, mixture, 5 or preparation contains one (1) or more active medicinal ingredients not hav- 6 ing a depressant effect on the central nervous system, and if the admixtures 7 are included therein in combinations, quantity, proportion, or concentration 8 that vitiate the potential for abuse of the substances which have a depressant 9 effect on the central nervous system. 10 SECTION 2. This act shall be in full force and effect on and after July 11 1, 2000.
STATEMENT OF PURPOSE
RS09322
The purpose of this proposed legislation is to add the drug
carisoprodol to Schedule IV, restricting prescriptions for this
drug to five refills or six months, and placing it in the tracking
system. This change is in response to the escalating abuse of this
drug.
FISCAL IMPACT
There will be no impact on the General Fund, no cost to the general
public or practitioners, and implementation of legislation will be
from the Board of Pharmacy dedicated funds.
CONTACT: Richard K. "Mick" Markuson, Director
Idaho State Board of Pharmacy
334-2356